Amgen 20190135 - A Phase 1B, Master Protocol Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Amg 510 In Subjects With Advanced Solid Tumors With Kras P.G12c Mutation
Posted Date: Sep 11, 2020
- Investigator: Davendra Sohal
- Specialties:
- Type of Study: Drug
The goal of this study is to evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult subjects with KRAS p.G12C mutant advanced solid tumors. The primary endpoints of this study are to measure dose limiting toxicities, occurrence of adverse events, and changes in ECGs, vitals, and lab values.
Criteria:
To Be Eligible: Must Have Pathologically Documented, Locally-Advanced Or Metastatic Malignancy With, Kras P.G12c Mutation, No Primary Brain Tumor, No Ppinal Cord Compression, Or Untreated, Or Symptomatic, Or Active Brain Metastases, Or Leptomeningeal Disease From Non-Brain Tumors, No Myocardial Infarction Within 6 Months, No Gi Disease Causing Inability To Take Oral Medication
Keywords:
Advanced Solid Tumors, Phase 1
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com